Evidence map›Paper›PMID 42459319›Full record

ArticleFrontiers in oncology2026

A dual-prototype morphological topology evolution network for clinically oriented brain tumor MRI segmentation.

Yuejun Yao, Cai Jing, Xing Wang, Yao Liu, Tanjun Wei, Yi Liu, Xianhai Li

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuejun Yao *Department of Neurosurgery, Dazhou Central Hospital, Dazhou, China.
Cai Jing *Department of Neurosurgery, Dazhou Central Hospital, Dazhou, China.
Xing WangDepartment of Neurosurgery, Dazhou Central Hospital, Dazhou, China.
Yao LiuDepartment of Pharmacy, Dazhou Integrated TCM & Western Medical Hospital, Dazhou, China.
Tanjun WeiDepartment of Pharmacy, Dazhou Integrated TCM & Western Medical Hospital, Dazhou, China.
Yi LiuDepartment of Neurosurgery, Dazhou Central Hospital, Dazhou, China.
Xianhai LiDepartment of Pharmacy, Dazhou Integrated TCM & Western Medical Hospital, Dazhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Automatic segmentation of brain tumor MRI images has important clinical significance for lesion localization, preoperative planning, and therapeutic efficacy assessment. To address the challenges of blurred boundaries, irregular morphology, and similar grayscale appearances between brain tumor regions and surrounding brain tissues, this study proposes a dual-prototype morphological evolution network. The proposed method adopts SegFormer as the backbone network and designs an adaptive dual-prototype representation module to enhance category discrimination through background and tumor prototypes. Meanwhile, a morphological evolution attention module is introduced to improve the model's perception of irregular boundaries and local structures through differentiable soft morphological operations. Experimental results show that the proposed method achieves an mIoU of 0.8479, an mDice of 0.8937, an mRecall of 0.9141, and an HD95 of 23.47 on the public brain tumor dataset. On the clinical brain tumor dataset, the corresponding values reach 0.7937, 0.8422, 0.8673, and 29.86, respectively. These results validate the effectiveness of the proposed method in brain tumor region recognition, boundary localization, and clinical auxiliary segmentation.

Indexed as

brain tumorclinical auxiliary diagnosismagnetic resonance imagingmedical image segmentationneuroimaging analysis

Identifiers

PMID42459319
PMCPMC13368512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.